The efficiency of two-level electrovectorcardiographic diagnostics of left ventricular hypertrophy in the medical examination of urban and rural population

Background. The incidence of arterial hypertension continues to grow. By 2025 the number of patients will increase to 1.5 billion that makes it necessary to develop and implement effective approaches in the diagnosis and treatment of hypertension in practical health care. Aim. Evaluate the effectiveness of two-level diagnostics of left ventricular hypertrophy (LVH). Materials and methods. The distance of the first level of LVH diagnostics in outpatient departments with a territorial is more than 20 km. It was performed by remote electrocardiography, including medical examination of the population. Automatic conclusion of the devices was sent to the personal office of the functional diagnostics doctor. At the second level, the electrocardiograph software was used to convert ECG-12 into a vectorcardiogram (VKG) to clarify LVH. The ECG reports were returned to the device of the doctor/paramedic for further work with the patient. When using scalar ECG criteria for LVH, the most sensitive index was the Sokolov-Lyon index - 24.2% of cases, then the Cornell product - 19.8% of cases. In the second level of ECG diagnostics, the sensitivity of the method in detecting LVH increased more than 3 times: in terms of the maximum loop vector modulus (M QRS 1.8 mV), 72%, the sensitivity of the total index Rx+Sz (2.7 mV) was 58% of cases, the deviation of the spatial angle QRS-T>90° was 42.5%, the spatial area of the loop QRS (S QRSxyz 2.7 mV2), the area of the loop QRS in the horizontal plane (S QRSxz>2.2 mV2) - 41.5%, the orientation angle of the maximum loop vector t in the horizontal plane (angle Txz>70°) was detected in 38% of patients. These indicators were found with the same frequency in both groups of examined individuals. Conclusion. The use of remote two-level ECG and ECG diagnostics allowed to increase the detection of LVH in rural and urban populations by 3 times.

arterial hypertension, left ventricular hypertrophy, remote electrocardiography, vectorcardiography

1. Vsemirnaia organizatsiia zdravookhraneniia, 63-ia sessiia Vsemirnoi assamblei zdravookhraneniia. Zheneva, 17–21 maia 2010 goda. Rezoliutsii i resheniia, grilozheniia (WHA63/2010/REC/1). Prilozhenie 4 (in Russian).

2. Chazova IE, Zhernakova YV. Diagnosis and treatment of arterial hypertension (Guidelines). Systemic Hypertension. 2019;16(1):6-31 (in Russian). doi: 10.26442/2075082X.2019.1.190179

3. 2018 ESC/ESH Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). Russian Journal of Cardiology. 2018;23(12):143-228 (in Russian). doi: 10.15829/1560-4071-2018-12-143-228

4. Chaykovskaya OYa, Ryabykina GV, Kozlovskaya IL, et al. The diagnostic value of electrocardiographic criteria for left ventricular hypertrophy in essential arterial hypertension alone and in combination with coronary heart disease. Medicinskij alfavit. 2019;1(8):14-20 (in Russian). doi: 10.33667/2078-5631-2019-1-8(383)-14-20

5. Blinova EV, Sakhnova TA, Saidova MA, et al. Informativnost' pokazatelei ortogonal'noi elektrokardiogrammy v diagnostike gipertrofii levogo zheludochka. Terapevticheskii Arkhiv (Ter. Arkh.). 2007;79(4):15-8 (in Russian).

6. Muromtseva GA, Deev AD, Konstantinov VV, et al. The Prevalence of Electrocardiographic Indicators among Men and Women of Older Ages in the Russian Federation. Rational Pharmacotherapy in Cardiology. 2016;12(6):711-7 (in Russian). doi: 10.20996/1819-6446-2016-12-6-711-717

7. Ryabykina GV, Blinova EV, Sakhnova TA. Electrovectorcardiographic diagnosis of right ventricular hypertrophy in patients with pulmonary hypertension. A guide for medical practitioners. Moscow, 2015; p. 18-25 (in Russian).

8. Sakhnova TA, Blinova EV, Yurasova ES. The spatial QRS-T angle and verticular gradient: diagnostic and prognostic value. Kardiologicheskij vestnik. 2017;2:70-5 (in Russian).

9. De Bie MK, Marsan AN, Gaasbeek A, et al. Echocardiographical determinants of an abnormal spatial QRS-T angle in chronic dialysis patients. Nephrol Dial Transplant. 2013;28(12):3045-52. doi: 10.1093/ndt/gft347

10. De Bie MK, Koopman MG, Gaasbeek A, et al. Incremental prognostic value of an abnormal baseline spatial QRS-T angle in chronic dialysis patients. Europace. 2013;15:290-6. doi: 10.1093/europace/eus306

11. Krivoshchekov SG, Shevchenko IV, Suvorova IYu. Clinical and physiological aspects left ventricular remodeling process in arterial hypertension. Vestnik Tiumenskogo gosudarstvennogo universiteta. Ekologiia i prirodopol'zovanie. 2015;1(3):183-99 (in Russian).

12. Kobalava ZhD, Kolesnik EL, Troitskaia EA. Current European guidelines on arterial hypertension: new positions and unsolved issues. Clinical pharmacology and therapy. 2019;28(2):7-18 (in Russian). doi: 10.32756/0869-5490-2019-2-7-18

13. Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387(10022):957-67. doi: 10.1016/S0140-6736(15)01225-8

14. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension: 7. Effects of more vs. less intensive blood pressure lowering and different achieved blood pressure levels – updated overview and meta-analyses of randomized trials. J Hypertens. 2016;34(4):613-22. doi: 10.1097/HJH.0000000000000881

15. Williamson JD, Supiano MA, Applegate WB, et al. Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged ≥75 years: A randomized clinical trial. JAMA. 2016;315(24):2673-82. doi: 10.1001/jama.2016.7050

16. Wald DS, Law M, Morris JK, et al. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med. 2009;122(3):290-300. doi: 10.1016/j.amjmed.2008.09.038

17. Chow CK, Teo KK, Rangarajan S, et al. Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. JAMA. 2013;310:959-68. doi: 10.1001/jama.2013.184182

18. Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021-104. doi: 10.1093/eurheartj/ehy339

19. Thomopoulos C, Parati G, Zanchetti A. Effects of blood-pressure-lowering treatment in hypertension: 9. Discontinuations for adverse events attributed to different classes of antihypertensive drugs: meta-analyses of randomized trials. J Hypertens. 2016;34(10):1921-32. doi: 10.1097/HJH.0000000000001052

20. Ridker PM, Danielson E, Fonseca FAH, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195-207. doi: 10.1056/NEJMoa0807646